ClinicalTrials.gg
TerminatedNCT05272813Updated Jul 18, 2024

A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

A Phase 1/2 interventional study of MS-553 in Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: Leukemia, LymphoidReclassifiedWhy we changed it
Registry
Leukemia, Lymphoid — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell, a narrower term within Leukemia, Lymphoid.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study is terminated due to major protocol revisions.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China — 39 open to participants now, 60 under way, 19 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · China.

Enrollment
92nd of 105
13 · median 89
Started
2022
with 10 others
Phase 1/2
27 of 108
10 open now
Registered
67th of 108
by date

Among the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, this one is the 92nd largest by enrollment of the 105 interventional ones that give a count, is one of 11 that started in 2022, is one of 27 in phase 1/2, and was the 67th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

39 of the 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

03

Conditions studied

  • Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Browse trials for

04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 13 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Lymphoid. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older, male or female.
  • Diagnosis of CLL/SLL per IWCLL2018 criteria.
  • Patients with CLL/SLL who have failed at least 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy), are indicated for treatment per IWCLL2018.
  • detected by contrast-enhanced computed tomography (CT): at least one lymph node with a maximum axis of more than 1.5 cm and one measurable vertical dimension.
  • performance status of 0 to 2.
  • Patients with an estimated survival of more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • -proven and confirmed current or past transformation to Richter's syndrome.
  • Patients with active and uncontrolled cytopenia, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura.
  • Patients who have received any of the following treatments within 14 days prior to the first dose:

    • Major surgery;
    • (at a dose equal to or greater than 20 mg/day prednisone or equivalent), unless used by inhalation, topical or intraarticular route, or unless necessary for premedication before and after iodinated contrast dye. After discussion with the Sponsor, steroid therapy at high doses for an extended period may be allowed under the following circumstances:

      1. Treatment of autoimmune hemolysis or autoimmune thrombocytopenia associated with CLL/SLL;
      2. Short-term (within 14 days) use to treat inactive infections of diseases unrelated to CLL/SLL (e.g. arthritis, asthma), which results in acute exacerbation, including steroid dose modifications required for adrenal insufficiency;
    • Cytotoxic chemotherapy or biologic therapy, excepting BCR pathway kinase inhibitors for which a of 24 hours prior to the first dose is required.
  • Toxicity from prior anti-tumor therapy (chemotherapy, radiotherapy, or biotherapy) did not restore to ≤ Grade 1 (except for alopecia); atrial fibrillation from prior treatment with BTK inhibitors did not restore to ≤ Grade 2.
  • Central nervous system (CNS) leukemia or lymphoma, including a history of asymptomatic, previously treated CNS disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    MS-553 Low Dose

    MS-553 Low Dose PO BID

    Drug: MS-553

  • Experimental
    MS-553 Mid Dose-1

    MS-553 Mid Dose-1 PO BID

    Drug: MS-553

  • Experimental
    MS-553 Mid Dose-2

    MS-553 Mid Dose-2 PO BID

    Drug: MS-553

  • Experimental
    MS-553 High Dose

    MS-553 High Dose PO BID

    Drug: MS-553

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities

    Time frame: 28 days

Secondary outcomes

  1. Incidence and severity of adverse events

    Time frame: Assessed throughout the study from the time of first dose of study drug until 30 days after the patient's last dose of study drug or until the event has resolved, stabilized, or an outcome reached, whichever comes first regardless of timing of EoT visit

  2. Overall response rate

    Time frame: up to 24 months

  3. Time to tumor response

    Time frame: During intervention

  4. Disease control rate

    Time frame: During intervention

  5. Progression free survival

    Time frame: During intervention

  6. Overall survival

    Time frame: During intervention

  7. Assessment of minimal residual disease

    Time frame: During intervention

08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Xicheng District, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Nov 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 9, 2022
StartActual
Apr 28, 2022
Primary completionActual
Nov 28, 2023
CompletionActual
Nov 28, 2023
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05272813
Lead sponsor
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Mar 9, 2022
Start date
Apr 28, 2022
Primary completion
Nov 28, 2023
Completion
Nov 28, 2023
Last update
Jul 18, 2024

Study contacts

Kai Zhang, MD
study director · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PKC-beta Inhibitor MS-553

Start the discussion